Cargando…

Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial

RASSF1 gene methylation predicts longer disease-free survival (DFS) and overall survival (OS) in patients with early-stage non-small-cell lung cancer treated using paclitaxel-based neo-adjuvant chemotherapy compared to patients receiving a gemcitabine-based regimen, according to the randomized Phase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dubois, Fatéméh, Keller, Maureen, Hoflack, Julien, Maille, Elodie, Antoine, Martine, Westeel, Virginie, Bergot, Emmanuel, Quoix, Elisabeth, Lavolé, Armelle, Bigay-Game, Laurence, Pujol, Jean-Louis, Langlais, Alexandra, Morin, Franck, Zalcman, Gérard, Levallet, Guénaëlle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966477/ https://www.ncbi.nlm.nih.gov/pubmed/31766357 http://dx.doi.org/10.3390/cancers11121835

Ejemplares similares

MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early–stage lung cancer patients from the IFCT-0002 Phase 3 Trial
por: Levallet, Guénaëlle, et al.
Publicado: (2016)

RASSF1A, puppeteer of cellular homeostasis, fights tumorigenesis, and metastasis—an updated review
por: Dubois, Fatéméh, et al.
Publicado: (2019)

A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT‐0701 MAPS phase 3 trial
por: Maille, Elodie, et al.
Publicado: (2022)

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial
por: Maille, Elodie, et al.
Publicado: (2019)

Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP
por: Dubois, Fatéméh, et al.
Publicado: (2022)

NDR2 kinase contributes to cell invasion and cytokinesis defects induced by the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells
por: Keller, Maureen, et al.
Publicado: (2019)

A role for RASSF1A in tunneling nanotube formation between cells through GEFH1/Rab11 pathway control
por: Dubois, Fatéméh, et al.
Publicado: (2018)

Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2
por: Darding, M, et al.
Publicado: (2011)

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)
por: Wislez, Marie, et al.
Publicado: (2022)

LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC
por: Yang, Chengcheng, et al.
Publicado: (2016)

Cytoplasmic and Nuclear Functions of cIAP1
por: Zadoroznyj, Aymeric, et al.
Publicado: (2022)

Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy
por: Bergot, Emmanuel, et al.
Publicado: (2013)

Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation
por: Gill, Catherine, et al.
Publicado: (2009)

Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency
por: Cheng, Le, et al.
Publicado: (2010)

Inhibitor of apoptosis proteins, NAIP, cIAP1 and cIAP2 expression during macrophage differentiation and M1/M2 polarization
por: Morón-Calvente, Virginia, et al.
Publicado: (2018)

Expression and Correlation of Cell-Free cIAP-1 and cIAP-2 mRNA in Breast Cancer Patients: A Study from India
por: Verma, Amit Kumar, et al.
Publicado: (2020)

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
por: Borget, Isabelle, et al.
Publicado: (2014)

E2F1 binds to the peptide-binding groove within the BIR3 domain of cIAP1 and requires cIAP1 for chromatin binding
por: Allègre, Jennifer, et al.
Publicado: (2018)

Deciphering Promoter Hypermethylation of Genes Encoding for RASSF/Hippo Pathway Reveals the Poor Prognostic Factor of RASSF2 Gene Silencing in Colon Cancers
por: Riffet, Marc, et al.
Publicado: (2021)

cIAP-1 Controls Innate Immunity to C. pneumoniae Pulmonary Infection
por: Prakash, Hridayesh, et al.
Publicado: (2009)

Activation of noncanonical NF-κB requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2, TRAF3 and the kinase NIK
por: Zarnegar, Brian J., et al.
Publicado: (2008)

Development and Validation of a Simplified Prognostic Score in SCLC
por: Negre, Elodie, et al.
Publicado: (2020)

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
por: Molinier, O., et al.
Publicado: (2021)

Bivalent IAP antagonists inhibit TRAF2-bound cIAPs and limit TNF-mediated NF-κB signaling
por: Condon, Stephen M
Publicado: (2016)

cIAP1 promotes proliferation and migration and prevents apoptosis in gallbladder cancer in vitro
por: Su, Wei, et al.
Publicado: (2019)

TRIM56 promotes malignant progression of glioblastoma by stabilizing cIAP1 protein
por: Yang, Xu, et al.
Publicado: (2022)

Bivalent IAP antagonists, but not monovalent IAP antagonists, inhibit TNF-mediated NF-κB signaling by degrading TRAF2-associated cIAP1 in cancer cells
por: Mitsuuchi, Y, et al.
Publicado: (2017)

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
por: Duruisseaux, Michaël, et al.
Publicado: (2017)

TAK1 kinase determines TRAIL sensitivity by modulating reactive oxygen species and cIAP
por: Morioka, Sho, et al.
Publicado: (2009)

HAX1 regulates E3 ubiquitin ligase activity of cIAPs by promoting their dimerization
por: Choi, Jin Sun, et al.
Publicado: (2014)

PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1
por: Guo, Haihong, et al.
Publicado: (2019)

Correction: cIAP1 promotes proliferation and migration and prevents apoptosis in gallbladder cancer in vitro
Publicado: (2019)

USP11: A key regulator of cIAP2 stability and sensitivity to SMAC mimetics
por: Lee, Eun-Woo, et al.
Publicado: (2015)

cIAP1/2 are involved in the radiosensitizing effect of birinapant on NSCLC cell line in vitro
por: Sun, Hao, et al.
Publicado: (2021)

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study
por: Girard, N., et al.
Publicado: (2022)

Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression
por: Paschall, Amy V, et al.
Publicado: (2014)

cIAPs Block Ripoptosome Formation, a RIP1/Caspase-8 Containing Intracellular Cell Death Complex Differentially Regulated by cFLIP Isoforms
por: Feoktistova, Maria, et al.
Publicado: (2011)

cIAP1 regulates the EGFR/Snai2 axis in triple-negative breast cancer cells
por: Majorini, Maria Teresa, et al.
Publicado: (2018)

cIAP2 promotes gallbladder cancer invasion and lymphangiogenesis by activating the NF‐κB pathway
por: Jiang, Xiaojie, et al.
Publicado: (2017)

RETRACTED ARTICLE: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_i9p5sq847ujk92gglriqrfk3ep